Industry – Page 6

Alector Cuts 17% of Workforce Following Failure of AbbVie-Partnered Alzheimer’s Drug in Phase 2 Trial

1 year ago talkbio0Tagged AbbVie, Alector, Alzheimer 's disease, Failure (biologic function), Industry, Phase 2 trial

Alector, layoffs, AbbVie, Alzheimer’s disease, phase 2 trial failure, biotech industry

Navigating JPM Week 2024: Insights and Opportunities in Biopharma

1 year ago talkbio0Tagged Biopharma, deal-making, Industry, Investments, IPOs, JPM, M&A, Network, regulatory, trends qualifier

JPM Week 2024, Biopharma, Industry Insights, Networking, Deal-making, Investment, M&A, IPOs, Regulatory Trends

Halozyme Therapeutics Abandons $2.1 Billion Acquisition Bid for Evotec Due to Lack of Engagement

1 year ago talkbio0Tagged Acquisition, Evotec, Halozyme, Industry, Twice a day, Withdraw (activity)

Halozyme Therapeutics, Evotec, acquisition bid, withdrawal, lack of engagement, biotech industry

CSL Behring to Close California R&D Site Amid Shift in Gene Therapy Strategy

1 year ago talkbio0Tagged Behring, California, ex vivo, gene therapy, Industry, R&D site closure, SMPX gene, strategic, trends qualifier

CSL Behring, California R&D site closure, ex vivo gene therapy, strategic repositioning, biotech industry trends

RFK Jr.’s HHS Nomination: A Potential Threat to the Biopharma Industry

1 year ago talkbio0Tagged Administration occupational activities, Biopharma, CHARGE Syndrome, Health Policy, Industry, nomination, RFK Jr., Skepticism, Transplant Registry Unified Management Program, Vaccines

RFK Jr., HHS nomination, biopharma industry, vaccine skepticism, health policies, Trump administration

Gilead Sciences and Kite Pharma Announce Layoffs, Closure of Seattle and Philadelphia Offices

1 year ago talkbio0Tagged Gilead Sciences, Industry, Kite Pharma, Office Closures, Philadelphia, restructuring, Seattle

Gilead Sciences, Kite Pharma, layoffs, office closures, Seattle, Philadelphia, biotech industry, restructuring

Charles River Laboratories Embarks on Restructuring, Closing 15 Smaller Sites Amid Declining Demand for Early Research Services

1 year ago talkbio0Tagged Charles, cost-cutting measures, Declining, Demand (clinical), Industry, Reparative closure, restructuring, River Laboratories

Charles River Laboratories, restructuring, site closures, declining demand, early research services, cost-cutting measures, biotech industry challenges.

WuXi AppTec Faces Uncertainty Amid BIOSECURE Act, Yet Continues to Secure New Projects

1 year ago talkbio0Tagged AppTec, Biopharma, BIOSECURE, CDMOs, Contract agreement, Industry, Legislation, manufacturing organizations, National Security Concerns, Outsourcing, United States, WuXi

BIOSECURE Act, WuXi AppTec, Biotechnology Industry, U.S. Legislation, Contract Development and Manufacturing Organizations (CDMOs), Biopharma Outsourcing, National Security Concerns